<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273765</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12300 REFLATE TB2</org_study_id>
    <nct_id>NCT02273765</nct_id>
  </id_info>
  <brief_title>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</brief_title>
  <acronym>REFLATE TB2</acronym>
  <official_title>Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III trial evaluating raltegravir as an alternative to efavirenz for antiretroviral&#xD;
      treatment of HIV-infected patients with tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III multicenter, international, open-label, randomized trial evaluating non-inferiority&#xD;
      of raltegravir at dose of 400mg BID compared to efavirenz 600mg QD, both in association with&#xD;
      tenofovir disoproxil fumarate and lamivudine in ART-naïve HIV-1 infected patients with active&#xD;
      TB disease receiving a rifampin-based TB treatment initiated &lt;8 weeks before inclusion.&#xD;
      Patients will be randomized between 2 arms: the raltegravir (RAL) 400 mg bid arm or the&#xD;
      efavirenz (EFV) 600 mg qd arm, each in combination with tenofovir disoproxil fumarate (TDF)&#xD;
      and lamivudine (3TC) and will be followed for 48 weeks after entry in the trial (ART&#xD;
      initiation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2015</start_date>
  <completion_date type="Actual">November 28, 2018</completion_date>
  <primary_completion_date type="Actual">November 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in virologic success</measure>
    <time_frame>Week 48</time_frame>
    <description>Virologic success, defined as plasma HIV-1 RNA &lt;50 copies/mL, at week 48 with a window period of 42 to 54 weeks (snapshot algorithm). Discontinuation of the strategy (ie. permanent discontinuation of EFV, RAL), missing values, loss to follow-up and death will be considered as failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to new or recurrent AIDS-defining illnesses</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to severe HIV-associated non-AIDS defining illnesses</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to grade 3 or 4 adverse events</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to drug-induced clinical or biological adverse reactions of grade 3 or 4 or leading to treatment interruption</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma HIV-1 RNA from baseline to week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in virologic success at each time point (HIV-1 RNA&lt;50 copies/mL)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virologic failure during follow-up</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and time to new antiretroviral genotypic resistance in plasma RNA in patients with virologic failure</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 cell counts from baseline to week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to Immune Reconstitution Inflammatory Syndrome</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of tuberculosis treatment outcomes</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>HIV-1 Infection</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300mg QD + lamivudine 300mg QD + raltegravir 400mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir 300mg QD + lamivudine 300mg QD + efavirenz 600mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + lamivudine + raltegravir</intervention_name>
    <description>In this arm, patients will receive the following medications :&#xD;
Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)&#xD;
Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food&#xD;
In countries where TDF/3TC FDC is not available, the following separate drugs will be used:&#xD;
Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)&#xD;
Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)&#xD;
Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + lamivudine + efavirenz</intervention_name>
    <description>In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:&#xD;
Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)&#xD;
Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)&#xD;
OR:&#xD;
• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food&#xD;
In countries where TDF/3TC FDC is not available, the following separate drugs will be used:&#xD;
Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)&#xD;
Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)&#xD;
Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight.</description>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Aged 18 years or more&#xD;
&#xD;
          -  Confirmed HIV-1 infection as documented at any time prior to trial entry per national&#xD;
             HIV testing procedures&#xD;
&#xD;
          -  ART naïve&#xD;
&#xD;
          -  For women of childbearing potential i.e. women of childbearing age who are not&#xD;
             menopausal, or permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral&#xD;
             salpingectomy) or not refraining from sexual activity: negative urinary test for&#xD;
             pregnancy and acceptance to use contraceptive methods&#xD;
&#xD;
          -  Confirmed or probable active TB disease of any location, except neurological&#xD;
             (meningitis or encephalitis), according to the following criteria based on WHO updated&#xD;
             definitions:&#xD;
&#xD;
               -  Bacteriologically confirmed pulmonary TB (PTB) or extrapulmonary TB (EPTB), e.g.&#xD;
                  TB with a biological specimen positive by smear microscopy, culture or nucleic&#xD;
                  acid amplification test (such as Xpert MTB/RIF).&#xD;
&#xD;
               -  Clinically diagnosed PTB or EPTB with typical histological evidence of TB&#xD;
                  (caseous or granulomatous) on biopsy specimen or positive urinary LAM test OR a&#xD;
                  significant improvement on TB treatment&#xD;
&#xD;
          -  Ongoing standard rifampin-containing TB treatment for ≤8 weeks at inclusion&#xD;
&#xD;
          -  For French patients, affiliation to a Social Security program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-2 co-infection&#xD;
&#xD;
          -  Impaired hepatic function (icterus or ALT (SGPT) &gt; 5ULN)&#xD;
&#xD;
          -  Hemoglobin &lt; 6.5 g/dl&#xD;
&#xD;
          -  Creatinine clearance &lt;60ml/min (assessed by the Cockroft and Gault formula)&#xD;
&#xD;
          -  Mycobacterium tuberculosis strain resistant to rifampin (current or past history).&#xD;
&#xD;
          -  Neurological TB (meningitis or encephalitis)&#xD;
&#xD;
          -  Severe associated diseases requiring specific treatment (including all specific AIDS&#xD;
             defining illnesses other than TB, and any severe sepsis)&#xD;
&#xD;
          -  Any condition which might, in the investigator's opinion, compromise the safety of&#xD;
             treatment and/or patient's adherence to trial procedures including very severe&#xD;
             TB-related clinical condition&#xD;
&#xD;
          -  Concomitant treatments including phenytoin or phenobarbital (compounds interacting&#xD;
             with UGT1A1)&#xD;
&#xD;
          -  For HCV co-infected patients, need to start specific treatment for hepatitis during&#xD;
             the trial duration&#xD;
&#xD;
          -  For women of childbearing potential:&#xD;
&#xD;
               -  Pregnancy or breastfeeding&#xD;
&#xD;
               -  Refusal to use a contraceptive method&#xD;
&#xD;
               -  Any history of ARV intake for prevention of mother to child transmission of HIV&#xD;
                  (pMTCT)&#xD;
&#xD;
          -  Subjects participating in another clinical trial evaluating therapies and including an&#xD;
             exclusion period that is still in force during the screening phase&#xD;
&#xD;
          -  Person under guardianship, or deprived of freedom by a judicial or administrative&#xD;
             decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatriz Grinsztejn, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Laboratory on Clinical research on DST/AIDS-IPEC FIOCRUZ Av Brasil, 4365 Manguinhos Rio de Janeiro, Brazil CEP 21040-900</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie De Castro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AP-HP Hôpital Saint-Louis 1 avenue Claude Vellefaux, 75010 Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PACCI / CePReF Centre de Prise en charge de Recherche et de Formation</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Saude / Hospital Geral de Machava</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pham Ngoc Thach Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Côte D'Ivoire</country>
    <country>France</country>
    <country>Mozambique</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>December 28, 2018</last_update_submitted>
  <last_update_submitted_qc>December 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

